We provide a 3D sketch-based design platform for cardiovascular surgeons so that they can create their intended surgeries before the in vivo execution in the computer. This surgical design platform is integrated to our cardiovascular engineering performance analysis package, where the clinical performance of the intended surgical anatomical configurations can be analyzed and predicted before the operation, for each patient. A number of novel features of our approach is protected through our 4 pending international patent applications.
Due to its relatively easier bedside translational potential and our ~15 years of expertise on this market sector, we initially focus on kids with heart defects. This strategy will also result major clinical impact since approximately 1 in 100 children are born with a clinically significant congenital heart defect (CHD), representing 1,500,000 children worldwide. Hospital costs for congenital cardiovascular defect conditions totaled $2.6 billion doll...
We provide a 3D sketch-based design platform for cardiovascular surgeons so that they can create their intended surgeries before the in vivo execution in the computer. This surgical design platform is integrated to our cardiovascular engineering performance analysis package, where the clinical performance of the intended surgical anatomical configurations can be analyzed and predicted before the operation, for each patient. A number of novel features of our approach is protected through our 4 pending international patent applications.
Due to its relatively easier bedside translational potential and our ~15 years of expertise on this market sector, we initially focus on kids with heart defects. This strategy will also result major clinical impact since approximately 1 in 100 children are born with a clinically significant congenital heart defect (CHD), representing 1,500,000 children worldwide. Hospital costs for congenital cardiovascular defect conditions totaled $2.6 billion dollars.
Recently we have interviewed 71 pediatric cardiologists and cardiovascular surgeons and identified two key products that focus the first-stage surgery of these defects. Our first product will be a triage tool so that inclusion of the newborn patient to the surgery can be determined through the numerical simulations of the patient’s cardiovascular system. The second product will focus on the surgical planning itself and anatomical optimization. The cardiologist agreed on benefits of the platform on simulating different surgical scenarios. Considering only the Turkish market, a net annual profit of $120,000 is estimated in two years.
The platform developed by Hemodyn Inc and Koc University provides virtual simulation of heart blood vessels based on mechanical models and produces a “hemodynamic analysis report” for each patient. This report list numerical values of parameters that are correlated to the physiological outcome. We will also provide 3D printing services to assist and control these complex surgeries. This way, surgeons can test any scenario on the platform instead of on the patient before the operation and test which ones could fail in terms of hemodynamics. Since the platform uses real patient data, such as Computer Tomography, Magnetic Resonance Imaging, Echocardiography, the produced model is considered realistic. There is no other technique or methodology exists that can predict surgical operation’s hemodynamic
More information

Investors

KWORKS '15
Admin
KWORKS '15 Build Something Amazing!